← Back to Search

Virus Therapy

Mitoquinone/mitoquinol mesylate for Coronavirus

Phase 1 & 2
Waitlist Available
Led By Theodoros Kelesidis, MD PHD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights

Summary

This trial tests if the Mito-MES dietary supplement can prevent severe symptoms in adults exposed to respiratory viruses like COVID-19. The supplement may help the body fight off severe symptoms.

Eligible Conditions
  • Coronavirus
  • Viral Respiratory Infection
  • Antiviral Treatment

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Viral Illness
Severity Score of Symptoms of Viral Illness
Secondary study objectives
Incidence of Treatment-Emergent Adverse Events as Assessed by the Proportion of Participants Exhibiting Adverse Events of Any Grade
Number of Participants With Any Symptoms of Viral Illness
Number of Participants With Fever

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MitoQExperimental Treatment1 Intervention
Treatment group
Group II: Control groupActive Control1 Intervention
Control group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mitoquinone/mitoquinol mesylate
2022
Completed Phase 2
~80

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,072 Previous Clinical Trials
1,056,182 Total Patients Enrolled
University of California, Los AngelesLead Sponsor
1,554 Previous Clinical Trials
10,264,034 Total Patients Enrolled
Theodoros Kelesidis, MD PHDPrincipal InvestigatorUniversity of Texas Southwestern Medical Center
1 Previous Clinical Trials
20 Total Patients Enrolled
~24 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top